20.74
0.02 (0.10%)
| Penutupan Terdahulu | 20.72 |
| Buka | 20.69 |
| Jumlah Dagangan | 3,343,584 |
| Purata Dagangan (3B) | 1,589,854 |
| Modal Pasaran | 3,536,058,112 |
| Harga / Pendapatan (P/E TTM) | 9.02 |
| Harga / Pendapatan (P/E Ke hadapan) | 46.73 |
| Harga / Jualan (P/S) | 3.22 |
| Harga / Buku (P/B) | 2.82 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2026 |
| Margin Keuntungan | 22.97% |
| Margin Operasi (TTM) | 7.90% |
| EPS Cair (TTM) | 1.37 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 18.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 14.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 7.32% |
| Nisbah Semasa (MRQ) | 2.88 |
| Aliran Tunai Operasi (OCF TTM) | 148.96 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 19.27 M |
| Pulangan Atas Aset (ROA TTM) | 5.56% |
| Pulangan Atas Ekuiti (ROE TTM) | 37.24% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | ACADIA Pharmaceuticals Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.50 |
|
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.57% |
| % Dimiliki oleh Institusi | 104.46% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Palo Alto Investors Lp | 31 Dec 2025 | 2,484,031 |
| Pictet Asset Management Holding Sa | 31 Dec 2025 | 1,547,103 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (UBS, 92.86%) | Beli |
| Median | 35.00 (68.76%) | |
| Rendah | 23.00 (Oppenheimer, 10.90%) | Pegang |
| Purata | 33.09 (59.55%) | |
| Jumlah | 9 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 24.86 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 04 Mar 2026 | 34.00 (63.93%) | Beli | 23.39 |
| Citizens | 26 Feb 2026 | 35.00 (68.76%) | Beli | 24.64 |
| 03 Feb 2026 | 34.00 (63.93%) | Beli | 24.76 | |
| RBC Capital | 26 Feb 2026 | 30.00 (44.65%) | Beli | 24.64 |
| 03 Feb 2026 | 31.00 (49.47%) | Beli | 24.76 | |
| Stifel | 26 Feb 2026 | 24.00 (15.72%) | Pegang | 24.64 |
| TD Cowen | 26 Feb 2026 | 37.00 (78.40%) | Beli | 24.64 |
| Wolfe Research | 24 Feb 2026 | 33.00 (59.11%) | Beli | 24.59 |
| Mizuho | 23 Feb 2026 | 35.00 (68.76%) | Beli | 24.73 |
| Oppenheimer | 06 Feb 2026 | 23.00 (10.90%) | Pegang | 23.56 |
| HC Wainwright & Co. | 03 Feb 2026 | 37.00 (78.40%) | Beli | 24.76 |
| Citigroup | 06 Jan 2026 | 36.00 (73.58%) | Beli | 26.94 |
| UBS | 06 Jan 2026 | 40.00 (92.86%) | Beli | 26.94 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 |
| 02 Feb 2026 | Pengumuman | Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union |
| 13 Jan 2026 | Pengumuman | Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |